Zanidatamab Plus Chemotherapy Prolongs PFS Over Trastuzumab Plus Chemotherapy in Patients with HER2-positive Advanced Gastro-Oesophageal Adenocarcinoma By Ogkologos - June 1, 2026 65 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HERIZON-GEA-01 study Source RELATED ARTICLESMORE FROM AUTHOR Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC High HPV Vaccination Coverage in England Associated with a Substantial Reduction in Cervical Cancer Mortality FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC MOST POPULAR Neoadjuvant Followed by Adjuvant Pembrolizumab Prolongs Event-Free Survival Compared to Adjuvant... March 8, 2023 Metastatic Colorectal Cancer May Spread Early in the Disease, Study Finds July 22, 2019 EMA Recommends Granting a Marketing Authorisation for Sugemalimab June 21, 2024 A Propensity Score Matched Study Supports the Use of Allogeneic HSCT... May 12, 2023 Load more HOT NEWS Alex Trebek Gets Choked Up Seeing Contestant’s Heartfelt ‘Guess’ As Final... Nivolumab and Relatlimab Combination Shows Promise in Advanced Melanoma Breast Cancer Patient Does Head-Shaving Photo Shoot in Hopes of Inspiring... Temporary Interruption of Adjuvant Endocrine Treatment to Attempt Pregnancy Does Not...
